Loading Complete
Kenneth J. Cohen

Kenneth J. Cohen, MD, MBA

Pediatric Medical Oncology

Neuro-Oncology

Pediatric Neuro-Oncology

Accepting New Patients

Highlights

Languages

  • English

Gender

Male

Johns Hopkins Affiliations:

  • Johns Hopkins School of Medicine Faculty

About Kenneth J. Cohen

Professional Titles

  • Clinical Director Pediatric Oncology
  • Director, Pediatric Neuro-Oncology
  • Director, Strategic Planning, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Primary Academic Title

Professor of Oncology

Background

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors.

Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas.  He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation.  He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries.

The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. 

Clinical Trial Keywords

Pediatric brain tumors, Neuro-Oncology

Additional Academic Titles

Professor of Pediatrics

Research Interests

Early-phase drug development for high-risk pediatric brain tumors

Research Summary

More children die of brain tumors than of any other type of pediatric cancer. Significant advances have been made in surgical and supportive care but with fewer evident therapeutic benefits. Dr. Cohen's clinical research focuses on the application of new therapeutics in children with high-risk brain tumors, with a particular focus on children with high-grade gliomas.

Selected Publications

  • Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children; a report from the Children’s Oncology Group.  Neuro Oncol. 2011 Mar;13(3):317-23

  • Cooney TM, Cohen KJ*, Guimaraes CV, Dhall G, Leach J, Massimino M, Erbetta A, Chiapparini L, Malbari F, Kramer K, Pollack IF, Baxter P, Laughlin S, Patay Z, Young Poussaint T, Warren KE. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 Jun;21(6):e330-e336

  • Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, André N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K. Nivolumab With or Without Ipilimumab in Pediatric Patients With High-Grade CNS Malignancies: Safety, Efficacy, Biomarker, and Pharmacokinetics: CheckMate 908. Neuro Oncol. 2023 Feb 20:

  • Naung H, Cohen KJ. An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity. J Neurooncol. 2021 May;152(3):567-572

  • Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120

Memberships

  • American Society of Clinical Oncology
  • American Society of Pediatric Hematology/Oncology
  • Society for Neuro-Oncology

Locations

  1. Johns Hopkins Children's Center
    • 1800 Orleans Street, Bloomberg 11N, Baltimore, MD 21287

    Expertise

    Education

    SUNY Upstate Medical University

    Medical Education, MD, 1987

    Board Certifications

    Pediatric Hematology-Oncology

    American Board of Pediatrics, 1994

    Insurance

    Johns Hopkins providers accept various commercial health insurance plans. However, they may not be included in all of an insurance company's plans or offerings. This may include Exchange, Medicaid, Medicare, and specific limited benefit plans. Exceptions to participation also exist based on your employer’s benefits package and the provider's location or specialty. Please contact your insurer directly to make sure your doctor is covered by your plan. For more details, please review our Insurance Information.
    Search plans
    • Aetna
    • CareFirst
    • Cigna
    • First Health
    • Geisinger Health Plan
    • HealthSmart/Accel
    • Humana
    • Johns Hopkins Health Plans
    • MultiPlan
    • Pennsylvania's Preferred Health Networks (PPHN)
    • Point Comfort Underwriters
    • Private Healthcare Systems (PHCS)
    • UnitedHealthcare
    • Veteran Affairs Community Care Network (Optum-VACCN)